(Q37340462)

19 August 2017

1 reference

title

Peptide-based vaccines for cancer: realizing their potential (English)

1 reference

19 August 2017

2

W Martin Kast

1 reference

19 August 2017

Shreya Kanodia

1

1 reference

19 August 2017

publication date

1 December 2008

1 reference

Expert Review of Vaccines

19 August 2017

published in

1 reference

19 August 2017

volume

7

1 reference

19 August 2017

issue

10

1 reference

19 August 2017

page(s)

1533-1545

1 reference

The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Peptide-induced antiviral protection by cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Design of peptide-based vaccines for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

More than one reason to rethink the use of peptides in vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Combinatorial peptide library methods for immunobiology research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

HLA-peptide binding prediction using structural and modeling principles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Empty MHC class I molecules come out in the cold

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Peptide selection by MHC class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Generation of glycosylated remnant epitopes from human collagen type II by gelatinase B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

T cells discriminate between differentially phosphorylated forms of alphaB-crystallin, a major central nervous system myelin antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

T cell recognition of the dominant I-A(k)-restricted hen egg lysozyme epitope: critical role for asparagine deamidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Citrullinated myelin basic protein induces experimental autoimmune encephalomyelitis in Lewis rats through a diverse T cell repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Post-translational modifications of naturally processed MHC-binding epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Link between organ-specific antigen processing by 20S proteasomes and CD8(+) T cell-mediated autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Heteroclitic immunization induces tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Optimizing vaccine design for cellular processing, MHC binding and TCR recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Mimotope vaccines for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Using a baculovirus display library to identify MHC class I mimotopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Anti‐tumor immune responses and tumor regression induced with mimotopes of a tumor‐associated T cell epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Mimotopes for tumor-specific T lymphocytes in human cancer determined with combinatorial peptide libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Epitope-based vaccines: an update on epitope identification, vaccine design and delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumor-infiltrating lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Beta-amino acids: versatile peptidomimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Improvement of the enzymatic stability of a cytotoxic T-lymphocyte-epitope model peptide for its oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

A cyclic chimeric interferon-alpha2b peptide induces apoptosis in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Increased adjuvant activity of minimal CD8 T cell peptides incorporated into lipid-core-peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Synthetic peptide epitope-based polymers: controlling size and determining the efficiency of epitope incorporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

The assembly and immunological properties of non-linear synthetic immunogens containing T-cell and B-cell determinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Cross-presentation in viral immunity and self-tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Therapeutics targeting the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Vaccine adjuvants revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Resiquimod and other immune response modifiers as vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Identification of a novel negative role of flagellin in regulating IL-10 production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

GM-CSF-based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Utilizing IL-12, IL-15 and IL-7 as Mucosal Vaccine Adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Type I interferons as vaccine adjuvants against infectious diseases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Adjuvant activity of incomplete Freund's adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

ISCOM-based vaccines: the second decade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

The potential of exosomes in immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Dendritic cell derived-exosomes: biology and clinical implementations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Epicutaneous application of CpG oligodeoxynucleotides with peptide or protein antigen promotes the generation of CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Initiation of adaptive immune responses by transcutaneous immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Evaluation of uptake and generation of immune response by murine dendritic cells pulsed with hepatitis B surface antigen-loaded elastic liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Taming cancer by inducing immunity via dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Taking dendritic cells into medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Dendritic cells and innate defense against tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Recognition of tumor glycans by antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Glycan modification of the tumor antigen gp100 targets DC-SIGN to enhance dendritic cell induced antigen presentation to T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Immune resistance orchestrated by the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Tumor escape mechanism governed by myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

The E75 HER2/neu peptide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.10.1533

10.1586/14760584.7.10.1533

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference